It was the purpose of the present investigation to extend the time course of post P5091 molecular weight ingestion measurement to 6 hours. Methods Ten exercise trained men (age = 24 ± 4 yrs; BMI = 25 ± 3 kg·m-2; body fat = 9 ± 3%; mean ± SD) SCH727965 and 10 exercise trained women (age = 22 ± 2 yrs; BMI = 23 ± 3 kg·m-2; body fat = 23 ± 5%; mean ± SD) ingested Meltdown® or a placebo, in a random order, double blind cross-over design, with one week separating conditions. Blood samples

were collected before and at one hour intervals throughout the 6 hour protocol. Samples through the 3 hour post ingestion period were obtained in a fasted state and a standard meal was provided after the hour 3 collection. Blood samples were assayed for EPI, NE, glycerol, and FFA. Breath samples were collected at each time for measurement of metabolic rate and

substrate utilization using indirect calorimetry. Area under the curve (AUC) was calculated for all variables. Heart rate and blood pressure were recorded at all collection times, and data were analyzed using a 2 (condition) × 7 (time) analysis of variance. Results AUC was greater for Meltdown® compared to placebo for EPI (367 ± 58 pg·mL-1·6 hr-1 vs. 183 ± 27 pg·mL-1·6 hr-1; p = 0.01), NE (2345 ± 205 pg·mL-1·6 hr-1 vs. 1659 ± 184 pg·mL-1·6 hr-1; p = 0.02), glycerol (79 ± 8 μg·mL-1·6 hr-1 vs. 59 ± 6 μg·mL-1·6 hr-1; p = 0.03), and FFA (2.46 ± 0.64 mmol·L-1·6 hr-1 vs. 1.57 ± 0.42 mmol·L-1·6 these hr-1; p = selleck compound 0.05). For all variables, values were highest between 1 and 3 hours post ingestion of Meltdown®. The AUC for kilocalorie expenditure was not statistically different (p = 0.12) for Meltdown® (449 ± 29 kcal·6 hrs-1) compared to placebo (392 ± 21 kcal·6 hrs-1), despite being 15% higher for Meltdown®. However, when only considering the AUC for kilocalorie expenditure from rest to hour 3 (prior to feeding), a difference was

noted (p = 0.05) for Meltdown® (224 ± 14 kcal·3 hrs-1) compared to placebo (187 ± 10 kcal·3 hrs-1). No difference (p = 0.32) was noted in AUC for substrate utilization between Meltdown® (4.83 ± 0.09·6 hrs-1) and placebo (5.04 ± 0.15·6 hrs-1). A condition main effect was noted for both systolic and diastolic blood pressure (p < 0.0001), with values increasing from a resting 111 ± 2/69 ± 2 mmHg to a peak of 124 ± 2/75 ± 2 mmHg at hour 3 with Meltdown®, while no change was noted for placebo. A condition main effect was noted for heart rate (p = 0.01), with values increasing from a resting 57 ± 2 bpm to a peak of 63 ± 2 bpm at hour 5 with Meltdown®, while no change was noted for placebo. Conclusion Ingestion of Meltdown® results in an increase in catecholamine secretion, markers of lipolysis, and metabolic rate in young men and women. An increase in hemodynamic variables is also noted, likely due to the catecholamine response to treatment.